Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine

NCT05909696•Yangzhou University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

SuccinylcholineMyofibrillation

Interventions

rocuronium

Locations

China

Locations (1)

the Affiliated Hospital of Yangzhou University, Yangzhou University

Yangzhou, Jiangsu, China

Key Dates

Start Date

July 1, 2023

Primary Completion Date

October 30, 2023

Completion Date

October 31, 2023

Last Updated

August 9, 2024

Sponsors

Lead Sponsor

Yangzhou University

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions